[go: up one dir, main page]

DE69920216D1 - Biologisches material zur herstellung pharmazeutischer zusammensetzungen zur behandlung von säugetieren - Google Patents

Biologisches material zur herstellung pharmazeutischer zusammensetzungen zur behandlung von säugetieren

Info

Publication number
DE69920216D1
DE69920216D1 DE69920216T DE69920216T DE69920216D1 DE 69920216 D1 DE69920216 D1 DE 69920216D1 DE 69920216 T DE69920216 T DE 69920216T DE 69920216 T DE69920216 T DE 69920216T DE 69920216 D1 DE69920216 D1 DE 69920216D1
Authority
DE
Germany
Prior art keywords
gene
pharmaceutical compositions
biological material
cell
mammals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69920216T
Other languages
English (en)
Other versions
DE69920216T2 (de
Inventor
Bruce Acres
Stephane Paul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene SA filed Critical Transgene SA
Application granted granted Critical
Publication of DE69920216D1 publication Critical patent/DE69920216D1/de
Publication of DE69920216T2 publication Critical patent/DE69920216T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69920216T 1998-10-22 1999-10-20 Biologisches material zur herstellung pharmazeutischer zusammensetzungen zur behandlung von säugetieren Expired - Fee Related DE69920216T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9813279 1998-10-22
FR9813279A FR2784997A1 (fr) 1998-10-22 1998-10-22 Materiel biologique pour la preparation de compositions pharmaceutiques destinees au traitement de mammiferes
PCT/FR1999/002551 WO2000024896A2 (fr) 1998-10-22 1999-10-20 Materiel biologique pour la preparation de compositions pharmaceutiques destinees au traitement de mammiferes

Publications (2)

Publication Number Publication Date
DE69920216D1 true DE69920216D1 (de) 2004-10-21
DE69920216T2 DE69920216T2 (de) 2005-09-22

Family

ID=9531887

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69920216T Expired - Fee Related DE69920216T2 (de) 1998-10-22 1999-10-20 Biologisches material zur herstellung pharmazeutischer zusammensetzungen zur behandlung von säugetieren

Country Status (12)

Country Link
US (1) US20050221435A1 (de)
EP (1) EP1084246B1 (de)
JP (1) JP2002528466A (de)
AT (1) ATE276364T1 (de)
AU (1) AU754505C (de)
CA (1) CA2344207A1 (de)
DE (1) DE69920216T2 (de)
DK (1) DK1084246T3 (de)
ES (1) ES2228115T3 (de)
FR (1) FR2784997A1 (de)
PT (1) PT1084246E (de)
WO (1) WO2000024896A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2435949A1 (fr) * 2001-01-26 2002-08-01 Transgene S.A. Materiel biologique pour la preparation de compositions pharmaceutiques destinees au traitement de mammiferes
JP2006501549A (ja) * 2002-09-30 2006-01-12 ゴールドマン，サックス アンド カンパニー 会社の資本構成を分析するための方法およびシステム
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
CN110546166B (zh) 2017-04-13 2024-03-29 艾吉纳斯公司 抗cd137抗体和其使用方法
US12234473B2 (en) 2020-12-31 2025-02-25 Immatics US, Inc. CD8 polypeptides, compositions, and methods of using thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
FR2758569B1 (fr) * 1997-01-20 1999-04-02 Centre Nat Rech Scient Materiel biologique pour le traitement d'un mammifere par transfert de gene d'anticorps et composition pharmaceutique le concernant

Also Published As

Publication number Publication date
ES2228115T3 (es) 2005-04-01
DK1084246T3 (da) 2005-01-31
CA2344207A1 (fr) 2000-05-04
US20050221435A1 (en) 2005-10-06
PT1084246E (pt) 2005-02-28
AU6344499A (en) 2000-05-15
WO2000024896A3 (fr) 2000-08-03
AU754505B2 (en) 2002-11-21
EP1084246A2 (de) 2001-03-21
WO2000024896A2 (fr) 2000-05-04
DE69920216T2 (de) 2005-09-22
JP2002528466A (ja) 2002-09-03
AU754505C (en) 2003-12-04
FR2784997A1 (fr) 2000-04-28
EP1084246B1 (de) 2004-09-15
ATE276364T1 (de) 2004-10-15

Similar Documents

Publication Publication Date Title
NO820090L (no) Fremgangsmaate for fremstilling og behandling av renninderivater
ES524816A0 (es) Procedimiento para la produccion de polipetidos mediante levadura.
ES2147553T3 (es) Vectores virales recombinantes para la expresion en unas celulas musculares.
ATE296875T1 (de) Verfahren zur herstellung von genetisch modifizierten cd34-negativen, adhärent wachsenden hämatopoietischen stammzellen
ES2085245T1 (es) Procedimiento para aislar acido nucleico.
BR9914643A (pt) Vetores adeno-associados para expressão dofator viii por células alvo
DE3586189D1 (de) Menge und verfahren zur herstellung rekombinierter erzeugnisse in grosser ausbeute.
DE69920216D1 (de) Biologisches material zur herstellung pharmazeutischer zusammensetzungen zur behandlung von säugetieren
WO2001019966A3 (en) Isolation of muscle-derived stem cells and uses therefor
DE69233245D1 (de) Verfahren zur Herstellung von Peptiden
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
DE3752391D1 (de) Rattenproteinkinase C und Verfahren zur Herstellung
KR970706838A (ko) 조혈 단백질을 사용한 적혈구생성을 자극하는 방법(methods for stimulating erythropoiesis using hematopoietic proteins)
Dao et al. Molecular control of cell cycle progression in primary human hematopoietic stem cells: methods to increase levels of retroviral-mediated transduction
Mahmoudi et al. An Elastin‐Derived Composite Matrix for Enhanced Vascularized and Innervated Bone Tissue Reconstruction: From Material Development to Preclinical Evaluation
HUP9800520A2 (hu) Génexpresszió emlős sejtekben
DE69837380D1 (de) Biologisches material zur behandlung eines säugetieres durch transfer einesfür einen antikörper kodierendes gen und eine pharmazeutische zusammensetzungdie diese enthält
DE3877136D1 (de) Rekombinantes histidinreiches protein von plasmodium falciparum, seine herstellung und verwendung.
ATE260339T1 (de) Antikörper gegen menschliches restrictin
JPH01108981A (ja) 修飾された脂質分解酵素、その製造方法およびこれを使用するリン脂質の加水分解方法
JPH07501695A (ja) Ｉｆｎ‐ガンマ‐アンタゴニストサイトカイン
Badieyan Establishing mRNA Delivery Systems for Conversion of Cell Differentiation Status
EP1220873A1 (de) Neue proteinkomponente und dafür kodierende nukleinsäure
DK544789A (da) Transkaryot implantering

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee